Meaghan A. Ransom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Meaghan A. Ransom has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer M. S. Sucre
Vanderbilt University Medical Center 4 Nashville, TN
4 shared publications - Heather H. Pua
Department of Pathology, Microbiology, and Immunology Vanderbilt University Medical Center Nashville Tennessee USA
2 shared publications - Alexander M. Blatt
Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center; Nashville, TN, USA
1 shared publication - Audrey N. Miller
Nationwide Children’s Hospital, Columbus, USA
1 shared publication Audrey Wood
Children’s Hospital of Philadelphia, Philadelphia, USA
1 shared publicationBrianna K. Brei
Children’s Nebraska and University of Nebraska Medical Center, Omaha, USA
1 shared publication
Latest Publications
- Open Access
- 26 October 2026
- Published by Springer Nature in Journal of Perinatology
- p. 1-6
Temporal trends and clinical factors associated with ketamine infusion in hospitalized infants with bronchopulmonary dysplasia
Objective: To characterize temporal trends in ketamine infusion use in extremely preterm infants with severe bronchopulmonary dysplasia (sBPD) and identify associated clinical factors. Study design: We conducted a 15-year (2010–2024) retrospective cohort study of extremely preterm infants with sBPD. Time was analyzed as a categorical variable in three 5-year epochs. Ketamine exposures were described, and multivariable logistic regression estimated associations between time periods and use, adjusting for clinical characteristics. Results: Among 8888 infants with sBPD, 112 (1.3%) received ketamine infusion, with use increasing over time and rising most sharply between 2020 and 2024. Pulmonary hypertension (adjusted odds ratio, aOR 5.47, 95% CI 1.65–18.09), stage II/III necrotizing enterocolitis (aOR 2.06, 1.24–3.43), and tracheostomy (aOR 8.32, 3.50–19.77) were independently associated with use. Conclusions: Ketamine infusions in sBPD are uncommon but have increased over time, particularly since 2020. Use is associated with markers of greater illness severity.
- 26 October 2026
- Published by Springer Nature in Journal of Perinatology
- p. 1-6
Open AccessTemporal trends and clinical factors associated with ketamine infusion in hospitalized infants with bronchopulmonary dysplasia
Objective: To characterize temporal trends in ketamine infusion use in extremely preterm infants with severe bronchopulmonary dysplasia (sBPD) and identify associated clinical factors. Study design: We conducted a 15-year (2010–2024) retrospective cohort study of extremely preterm infants with sBPD. Time was analyzed as a categorical variable in three 5-year epochs. Ketamine exposures were described, and multivariable logistic regression estimated associations between time periods and use, adjusting for clinical characteristics. Results: Among 8888 infants with sBPD, 112 (1.3%) received ketamine infusion, with use increasing over time and rising most sharply between 2020 and 2024. Pulmonary hypertension (adjusted odds ratio, aOR 5.47, 95% CI 1.65–18.09), stage II/III necrotizing enterocolitis (aOR 2.06, 1.24–3.43), and tracheostomy (aOR 8.32, 3.50–19.77) were independently associated with use. Conclusions: Ketamine infusions in sBPD are uncommon but have increased over time, particularly since 2020. Use is associated with markers of greater illness severity.
- Open Access
- 15 September 2026
- Published by Springer Nature in Journal of Perinatology
- p. 1-3
Neurodevelopmental therapy in NICUs that care for infants with bronchopulmonary dysplasia
- 15 September 2026
- Published by Springer Nature in Journal of Perinatology
- p. 1-3
Open AccessNeurodevelopmental therapy in NICUs that care for infants with bronchopulmonary dysplasia
- 1 May 2024
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 326 (5) , L517-L523
The emerging role of extracellular vesicles in bronchopulmonary dysplasia
Extracellular vesicle (EV) biology in neonatal lung development and disease is a rapidly growing area of investigation. Although EV research in the neonatal population lags behind EV research in adult lung diseases, recent discoveries demonstrate promise in furthering our understanding of the pathophysiology of bronchopulmonary dysplasia and the potential use of EVs in the clinical setting, as both biomarkers and therapeutic agents. This review article explores some of the recent advances in this field and our evolving knowledge of the role of EVs in bronchopulmonary dysplasia.
- 1 May 2024
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 326 (5) , L517-L523
The emerging role of extracellular vesicles in bronchopulmonary dysplasia
Extracellular vesicle (EV) biology in neonatal lung development and disease is a rapidly growing area of investigation. Although EV research in the neonatal population lags behind EV research in adult lung diseases, recent discoveries demonstrate promise in furthering our understanding of the pathophysiology of bronchopulmonary dysplasia and the potential use of EVs in the clinical setting, as both biomarkers and therapeutic agents. This review article explores some of the recent advances in this field and our evolving knowledge of the role of EVs in bronchopulmonary dysplasia.
- 1 March 2023
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 324 (3) , L385-L392
Developmental trajectory of extracellular vesicle characteristics from the lungs of preterm infants
Extracellular vesicles (EVs) are secreted lipid-enclosed particles that have emerged as potential biomarkers and therapeutic agents in lung disease, including bronchopulmonary dysplasia (BPD), a leading complication of preterm birth. Many unanswered questions remain about the content and cargo of EVs in premature infants and their role in lung development. To characterize EVs during human lung development, tracheal aspirates were collected from premature neonates between 22 and 35 wk gestational age and analyzed via nanoparticle tracking analysis, electron microscopy, and bead-based flow cytometry. EVs were detectable across late canalicular through saccular stages of lung development, demonstrating larger sizes earlier in gestation. EVs contained an abundance of the EV-enriched tetraspanins CD9, CD63, and CD81, as well as epithelial cell and immune cell markers. Increases in select surface proteins (CD24 and CD14) on EVs were associated with gestational age and with the risk of BPD. Finally, query of expression data obtained from epithelial cells in a single-cell atlas of murine lung development found that epithelial EV marker expression also changes with developmental time. Together, these data demonstrate an association between EV profile and lung development and provide a foundation for future functional classification of EVs, with the goal of determining their role in cell signaling during development and harnessing their potential as a new therapeutic target in BPD.
- 1 March 2023
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 324 (3) , L385-L392
Developmental trajectory of extracellular vesicle characteristics from the lungs of preterm infants
Extracellular vesicles (EVs) are secreted lipid-enclosed particles that have emerged as potential biomarkers and therapeutic agents in lung disease, including bronchopulmonary dysplasia (BPD), a leading complication of preterm birth. Many unanswered questions remain about the content and cargo of EVs in premature infants and their role in lung development. To characterize EVs during human lung development, tracheal aspirates were collected from premature neonates between 22 and 35 wk gestational age and analyzed via nanoparticle tracking analysis, electron microscopy, and bead-based flow cytometry. EVs were detectable across late canalicular through saccular stages of lung development, demonstrating larger sizes earlier in gestation. EVs contained an abundance of the EV-enriched tetraspanins CD9, CD63, and CD81, as well as epithelial cell and immune cell markers. Increases in select surface proteins (CD24 and CD14) on EVs were associated with gestational age and with the risk of BPD. Finally, query of expression data obtained from epithelial cells in a single-cell atlas of murine lung development found that epithelial EV marker expression also changes with developmental time. Together, these data demonstrate an association between EV profile and lung development and provide a foundation for future functional classification of EVs, with the goal of determining their role in cell signaling during development and harnessing their potential as a new therapeutic target in BPD.
- Open Access
- 7 April 2022
- Published by Springer Nature in Pediatric Research
- Vol. 93 (1) , 154-159
Bronchopulmonary dysplasia is associated with polyhydramnios in a scan for novel perinatal risk factors
Background The pathogenesis of bronchopulmonary dysplasia (BPD) is multifactorial, and there are limited data about prenatal exposures and risk of BPD. Study design Our study performed parallel analyses using a logistic regression model in a cohort of 4527 infants with data from a curated registry and using a phenome wide association study (PheWAS) based on ICD9/10-based phecodes. We examined 20 prenatal exposures from a neonatal intensive care unit (NICU) curated registry database related to pregnancy and maternal health as well as 94 maternal diagnosis phecodes with a PheWAS analysis. Result In both the curated registry and PheWAS analyses, polyhydramnios was associated with an increased risk of BPD (OR 5.70, 95% CI 2.78–11.44, p = 1.37 × 10−6). Conclusion Our data suggest that polyhydramnios may be a clinical indicator of premature infants at increased risk for bronchopulmonary dysplasia. Combining curated registry data with PheWAS analysis creates a valuable tool to generate hypotheses. Impact Polyhydramnios was significantly associated with bronchopulmonary dysplasia in both a curated registry and by ICD coding analysis with a phenome wide association study (PheWAS). Preterm polyhydramnios may be a clinical indicator of infants at increased risk for developing bronchopulmonary dysplasia after preterm birth. Combining curated registry with PheWAS analysis creates a valuable tool to generate hypotheses about perinatal risk factors and morbidities associated with preterm birth.
- 7 April 2022
- Published by Springer Nature in Pediatric Research
- Vol. 93 (1) , 154-159
Open AccessBronchopulmonary dysplasia is associated with polyhydramnios in a scan for novel perinatal risk factors
Background The pathogenesis of bronchopulmonary dysplasia (BPD) is multifactorial, and there are limited data about prenatal exposures and risk of BPD. Study design Our study performed parallel analyses using a logistic regression model in a cohort of 4527 infants with data from a curated registry and using a phenome wide association study (PheWAS) based on ICD9/10-based phecodes. We examined 20 prenatal exposures from a neonatal intensive care unit (NICU) curated registry database related to pregnancy and maternal health as well as 94 maternal diagnosis phecodes with a PheWAS analysis. Result In both the curated registry and PheWAS analyses, polyhydramnios was associated with an increased risk of BPD (OR 5.70, 95% CI 2.78–11.44, p = 1.37 × 10−6). Conclusion Our data suggest that polyhydramnios may be a clinical indicator of premature infants at increased risk for bronchopulmonary dysplasia. Combining curated registry data with PheWAS analysis creates a valuable tool to generate hypotheses. Impact Polyhydramnios was significantly associated with bronchopulmonary dysplasia in both a curated registry and by ICD coding analysis with a phenome wide association study (PheWAS). Preterm polyhydramnios may be a clinical indicator of infants at increased risk for developing bronchopulmonary dysplasia after preterm birth. Combining curated registry with PheWAS analysis creates a valuable tool to generate hypotheses about perinatal risk factors and morbidities associated with preterm birth.